An observational study in cGVHD, sponsored by Incyte Corporation. Recruiting at 37 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Incyte Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation — 4 open to participants now, 8 under way, 4 of them phase 3. Bronchiolitis Obliterans Syndrome · Incyte Corporation.
Among the 12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation, this one is the only one that started in 2023, is the only observational one, and was the 5th registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →4 of the 12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–17
Incyte Corporation · Sites in United States
Ages 18+
Incyte Corporation · Sites in United States, Australia, Austria and 10 more countries
Ages 12+
By country, each count listing its studies:
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 6
First in 2017; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 108 across 126 observational studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 60 across the 11 interventional studies, 1,500 across the 1 observational. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
3 of the studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585774Phase 3Incyte CorporationA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2027-09-28 |
| NCT06843408Incyte CorporationA Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | 2027-01-06 |
| NCT05919511Incyte CorporationObservational Study for Patients at Risk for Chronic Graft-Versus-Host Disease | 2027-10-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Participants greater than or equal to 18 years of age who have had Allogenic SCT 90 to 180 days prior to enrollment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Equal or Greater than 18 years old post alloSCT
Other: Non-Interventional
This is an observational study
Overall Burden of cGVHD diagnosis and severity
Time frame: 36 months
To describe personal and healthcare resources associated with the management of cGVHD
Time frame: 36 months
To describe changes in the proteomic, cytologic and molecular profile in blood, serum and saliva cGVHD
Time frame: Up to 36 months
Not enrolling at this site — choose another above.
Plan to share: No
Started Aug 2023 (actual). Primary completion is estimated for Oct 2027, 50 months after the start.
Of 57 observational studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bronchiolitis Obliterans Syndrome →